Recently, researchers have shown that the outcome of patients with advanced hematologic cancers who relapse following allogeneic hematopoietic stem cell transplantation (HSCT) may be greatly improved with an immunotherapy drug.
In this Leukemia & Lymphoma Society video, watch this film sponsored by GE in which researchers Carl June, M.D., David Porter, M.D., and Steven Grupp, M.D. talk about patient Emily “Emma” Whitehead and the “experimental immunotherapy therapy that utilizes engineered T cells to successfully kill cancer”
Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?